Hoimes, C. J., Graff, J. N., Tagawa, S. T., Hwang, C., Kilari, D., Ten Tije, A. J., … Antonarakis, E. S. (2020). KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Hoimes, Christopher J., Julie N. Graff, Scott T. Tagawa, Clara Hwang, Deepak Kilari, A. J. Ten Tije, Aurelius Omlin, et al. “KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Ten Tije AJ, et al. KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Hoimes, Christopher J., et al. “KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Ten Tije AJ, Omlin A, McDermott RS, Vaishampayan UN, Elliott T, Gerritsen WR, Wu H, Kim J, Schloss C, De Bono JS, Antonarakis ES. KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2020.